CONTEXT.—: Ultrastaging of sentinel lymph nodes (SLNs) is a crucial aspect in the approach to SLN processing. No consensual protocol for pathologic ultrastaging has been approved by international societies to date. OBJECTIVE.—: To provide a review of the ultrastaging protocol and all its aspects related to the processing of SLNs in patients with cervical cancer. DATA SOURCES.—: In total, 127 publications reporting data from 9085 cases were identified in the literature. In 24% of studies, the information about SLN processing is entirely missing. No ultrastaging protocol was used in 7% of publications. When described, the differences in all aspects of SLN processing among the studies and institutions are substantial. This includes grossing of the SLN, which is not completely sliced and processed in almost 20% of studies. The reported protocols varied in all aspects of SLN processing, including the thickness of slices (range, 1-5 mm), the number of levels (range, 0-cut out until no tissue left), distance between the levels (range, 40-1000 μm), and number of sections per level (range, 1-5). CONCLUSIONS.—: We found substantial differences in protocols used for SLN pathologic ultrastaging, which can impact sensitivity for detection of micrometastases and even small macrometastases. Since the involvement of pelvic lymph nodes is the most important negative prognostic factor, such profound discrepancies influence the referral of patients to adjuvant radiotherapy and could potentially cause treatment failure. It is urgent that international societies agree on a consensual protocol before SLN biopsy without pelvic lymphadenectomy is introduced into routine clinical practice.

Gynecologic Oncology Center Department of Obstetrics and Gynecology 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Institute of Pathology 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc22006746

003      

CZ-PrNML

005      

20230119135705.0

007      

ta

008      

220216s2019 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.5858/arpa.2019-0249-RA $2 doi

035    __

$a (PubMed)31869245

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Dundr, Pavel, $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic $d 1971- $7 xx0080436

245    10

$a Pathologic Protocols for Sentinel Lymph Nodes Ultrastaging in Cervical Cancer / $c P. Dundr, D. Cibula, K. Němejcová, I. Tichá, M. Bártů, R. Jakša

520    9_

$a CONTEXT.—: Ultrastaging of sentinel lymph nodes (SLNs) is a crucial aspect in the approach to SLN processing. No consensual protocol for pathologic ultrastaging has been approved by international societies to date. OBJECTIVE.—: To provide a review of the ultrastaging protocol and all its aspects related to the processing of SLNs in patients with cervical cancer. DATA SOURCES.—: In total, 127 publications reporting data from 9085 cases were identified in the literature. In 24% of studies, the information about SLN processing is entirely missing. No ultrastaging protocol was used in 7% of publications. When described, the differences in all aspects of SLN processing among the studies and institutions are substantial. This includes grossing of the SLN, which is not completely sliced and processed in almost 20% of studies. The reported protocols varied in all aspects of SLN processing, including the thickness of slices (range, 1-5 mm), the number of levels (range, 0-cut out until no tissue left), distance between the levels (range, 40-1000 μm), and number of sections per level (range, 1-5). CONCLUSIONS.—: We found substantial differences in protocols used for SLN pathologic ultrastaging, which can impact sensitivity for detection of micrometastases and even small macrometastases. Since the involvement of pelvic lymph nodes is the most important negative prognostic factor, such profound discrepancies influence the referral of patients to adjuvant radiotherapy and could potentially cause treatment failure. It is urgent that international societies agree on a consensual protocol before SLN biopsy without pelvic lymphadenectomy is introduced into routine clinical practice.

650    17

$a nádory děložního čípku $x diagnóza $7 D002583 $2 czmesh

650    17

$a protokoly protinádorové léčby $7 D024221 $2 czmesh

650    _7

$a sentinelová uzlina $x patologie $7 D000071036 $2 czmesh

650    _7

$a staging nádorů $x metody $x normy $7 D009367 $2 czmesh

650    _7

$a lidé $7 D006801 $2 czmesh

655    _2

$a časopisecké články $7 D016428

655    _7

$a práce podpořená grantem $7 D013485 $2 czmesh

655    _7

$a přehledy $7 D016454 $2 czmesh

700    1_

$a Cibula, David, $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic $d 1968- $7 jo20000074072

700    1_

$a Němejcová, Kristýna $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic $7 xx0233214

700    1_

$a Stružinská, Ivana $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic $7 xx0137560

700    1_

$a Bártů, Michaela $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic $7 xx0233216

700    1_

$a Jakša, Radek $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic $7 xx026017301

773    0_

$w MED00000558 $t Archives of pathology & laboratory medicine $x 1543-2165 $g č. - (2019)

856    41

$u https://pubmed.ncbi.nlm.nih.gov/31869245 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20220216 $b ABA008

991    __

$a 20230119135658 $b ABA008

999    __

$a kom $b bmc $g 1760730 $s 1157918

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2019 $c - $e 20191223 $i 1543-2165 $m Archives of pathology & laboratory medicine $n Arch Pathol Lab Med $x MED00000558

GRA    __

$a NV16-31643A $p MZ0

LZP    __

$c NLK120 $d 20230119 $a 2021-granty